VA research during the COVID-19 pandemic

Overview News Briefs Selected Studies by VA Researchers Clinical Trials Laboratory Studies Data Analysis/Review Other Research Commentary Active and Recently Completed Research Clinical trials Observational studies Data analysis projects Other research activities COVID-19 work highlighted on HSR&D site Useful links

COVID-19 FACT SHEET Download PDF For VA investigators: Please check our funding page for news about new funding opportunities relating to COVID-19.

Overview

In response to the COVID-19 pandemic, VA Research has undertaken a wide array of activities to support and advance VA's clinical and research missions and help Veterans affected by the disease. These efforts have spanned biomedical research, therapeutics and vaccine clinical trials, and data analyses that leverage VA's rich electronic health record system. VA Research has coordinated closely with internal VA and external partners—such as the National Institutes of Health and other federal agencies, and pharmaceutical companies—to identify the areas in which VA's nationwide research capacity, resources, and infrastructure could make the greatest contribution.

On this web page, we summarize recent and current COVID-19 research across the VA system.

News Briefs

COVID-19 boosters effective against Omicron and Delta variants
COVID-19 vaccine boosters were highly effective against recent virus variants, found a study by VA White River Junction researchers and colleagues. The study included data on more than 110,000 Veterans, mostly older and male, who had a COVID test between November 2021 and January 2022. Protection against both the Omicron and Delta COVID-19 variants was better in those who also had a booster dose of an mRNA vaccine, compared with those with only a two-dose vaccine. Boosters were 64% effective against Omicron infection, while initial vaccination was only 12% effective. For the Delta variant, booster vaccination was 90% effective, versus 54% for initial vaccination. Booster doses were 89% effective during the Omicron period and 94% effective during the Delta period at preventing hospitalization. Against hospitalization, two-dose vaccines were 63% effective against Omicron and 75% effective against Delta. With a booster dose, vaccines were 94% effective at preventing death during Omicron and 96% against Delta. The results show that vaccine boosters increase the effectiveness of COVID-19 vaccination against infection, hospitalization, and death, according to the researchers. (BMJ Open, Aug. 3, 2022)

Monoclonal antibody treatment could lower risk of death for hospitalized COVID-19 patient
A monoclonal antibody treatment improved survival in patients hospitalized with COVID-19, in an international clinical trial involving VA researchers. The study was part of ACTIV-3, a COVID-19 research program including many VA sites. Researchers randomly assigned more than 1,400 hospitalized patients to receive either the monoclonal antibody medication tixagevimab-cilgavimab (now called Evusheld) or placebo. Monoclonal antibodies are antibodies made in a laboratory. An infusion of the monoclonal antibodies resulted in 30% lower mortality, compared with standard care alone. The medication did not shorten recovery time. The drug was also shown to be safe, with the same percentage of adverse events occurring in both groups. The results suggest that this drug could be a useful treatment option for patients hospitalized with COVID-19, say the researchers. (Lancet Respiratory Medicine, July 8, 2022)

Sickle cell trait linked to increase risk of COVID-19 death
Sickle cell trait is linked to an increased risk of death from COVID-19, found a VA Million Veteran Program study. People with sickle cell trait have one sickle cell gene and one normal gene. Those with the trait usually do not have symptoms of sickle cell disease—a blood disorder primarily affecting people of African descent. Researchers studied MVP data of nearly 3,000 people with sickle cell trait, 13% of whom contracted COVID-19. They compared them to nearly 130,000 people without sickle cell trait, 10% of whom had COVID-19. Those with sickle cell trait had higher odds of death from COVID-19. The sickle cell group also had increased rates of acute kidney failure. About 21% of COVID-19 deaths were due to acute kidney failure for patients with sickle cell trait. The results strongly support including sickle cell trait as a risk factor for worse COVID-19 outcomes, say the researchers. (JAMA Internal Medicine, June 27, 2022)

Few differences in safety of Moderna, Pfizer COVID-19 vaccines
Both the Moderna and Pfizer COVID-19 vaccines have a low risk of adverse events, found a study by VA Boston researchers. The study looked at data on more than 400,000 Veterans who were vaccinated. Risks were low after 38 weeks for either vaccine. Veterans receiving the Moderna vaccine were slightly less likely to experience stroke, heart attack, blood clots, or kidney damage. However, the difference was less than two-tenths of one percent. The results show that either vaccine is safe and effective for individuals, say the researchers, but the differences may help inform future population-level vaccination efforts. (JAMA Internal Medicine, June 13, 2022)

Airborne virus linked to hospital COVID-19 spread
Hospital COVID-19 infection may result from airborne virus particles introduced by employees and patients in common hospital areas, according to a study by VA Boston researchers and colleagues. The researchers studied the genome sequence of viruses from infected nurses and patients during a hospital COVID-19 outbreak. They compared these to virus particles from air samples. They learned that viruses found in nurses and patients were genetically identical to virus particles in the air. The findings suggest that very small, aerosolized virus particles can lead to COVID-19 spread in hospitals, according to the researchers. Isolating infected health care providers and improving ventilation and masking could help decrease the spread, they say. (JAMA Network Open, June 8, 2022)

View all studies

⇑

Selected Studies by VA Researchers

Clinical Trials

Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomized, double-blind placebo-controlled trial. Wolfe CR, Tomashek KM, Patterson TF, Gomez CA, Marconi VA, Jain MK, Yang OO et al. In hospitalized patients with COVID-19 requiring supplemental oxygen, baricitinib plus remdesivir and dexamethasone plus remdesivir resulted in similar mechanical ventilation-free survival by day 29, but dexamethasone was associated with significantly more adverse events. Lancet Respir Med. 2022 May 23. Online ahead of print.

A multicenter evaluation of the Seraph 100 microbind affinity blood filter for the treatment of severe COVID-19. Chitty SA, Mobbs S, Rifkin BS, Stogner SW, Lewis MS, Betancort J, DellaVolpe J et al. Findings suggest that broad spectrum, pathogen agnostic blood purification can be safely deployed to meet new pathogen threats while awaiting targeted therapies and vaccines. Crit Care Explor. 2022 Mar 25;4(4):e0662.

Efficacy and safety of baricitinib plus standard care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: An exploratory, randomised placebo-controlled trial. Ely EW, Ramanan AV, Kartman CE, de Bono S, Liao R, Piruzeli MLB, Goldman JD et al. In a small exploratory study of critically ill, hospitalized COVID-19 patients on ventilation or extracorporeal membrane oxygenation, treatment with baricitinib reduced mortality. Lancet Respir Med. 2022 Feb 3. Online ahead of print.

The effect of povidone-iodine nasal spray on COVID-19 nasopharyngeal viral load in patients: A randomized control trial. Zarabanda D, Vukkadala N, Phillips KM, Qian ZJ, Mfuh KO, Hatter M, Lee IT et al. Data suggest that dilute version of povidone-iodine nasal spray are safe for topical use in the nasal cavity, but that the spray does not demonstrate virucidal activity in COVID-19 positive outpatients. Laryngoscope. 2021 Nov 1. Online ahead of print.

Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): A randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. Marconi VC, Ramanan AV, de Bono S, Kartman CE, Krishnan V, Liao R, Piruzeli ML et al. Although there was no significant reduction in the frequency of disease progression overall, treatment with baricitinib in addition to standard of care (including dexamethasone) had a similar safety profile to that of standard care alone, and was associated with reduced mortality in hospitalized adults with COVID-19. Lancet Respir Med. 2021 Aug 31. Online ahead of print.

⇑

Laboratory Studies

SARS-CoV-2 reinfection across a spectrum of immunological states. McKittrick JM, Burke TW, Petzold E, Sempowski GD, Denny TN, Polage CR, Tsalik EL, McClain MT. Repeat episodes of COVID-19 can occur in patients regardless of the presence of known risk factors or level of serological response to infection. Health Sci Rep. 2022 Jul 22;5(4):e554.

Potential similarities in sex difference in key genes and their expression network, EQTL and pathways between COVID-19 and chronic kidney disease based on mouse model. Yu Z, Zhan J, Dong W, Lu L, Jablonski MM, Aleya L, Chen J et al. Known and novel genes in chronic kidney disease may play significant roles in the sex differences in the chronic kidney disease and COVID-19 disease pathways. J Pers Med. 2022 Jul 21;12(7):1190.

Ultrafast-UV laser integrating cavity device for inactivation of SARS-CoV-2 and other viruses. Ambardar S, Howell MC Jr, Mayilsamy K, McGill A, Green R, Mohapatra S, Voronine DV, Mohapatra SS. An ultraviolet laser device has potential for inactivating SARS-CoV-2 viruses in air and water purification systems. Sci Rep. 2022 Jul 13;12(1):11935.

Simulation of COVID-19 symptoms in a genetically engineered mouse model: Implications for the long haulers. Singh M, Pushpakumar S, Bard N, Zheng Y, Homme RP, Mokshagundam SPL, Tyagi SC. The engineered mouse appears to be a suitable model for studying COVID-19 and finding appropriate prevention and treatment methods. Mol Cell Biochem. 2022 Jun 22. Online ahead of print.

Multiomic analysis reveals cell-type-specific molecular determinants of COVID-19 severity. Zhang S, Cooper-Knock J, Weimer AK, Shi M, Zozhaya L, Unutmaz D, Harvey C et al. The study identified a possible genomic basis for COVID-19 severity. Cell Syst. 2022 Jun 3. Online ahead of print.

⇑

Data Analysis/Review

Can we use temperature measurements to identify pre-symptomatic SARS-CoV-2 infection in nursing home residents? Elhamamsy S, DeVone F, Bayer T, Halladay C, Cadieux M, McConeghy K, Rajan A et al. Early temperature trends may identify COVID-19 infection in pre-symptomatic long-term care residents. J AM Geriatr Soc. 2022 Aug 4. Online ahead of print.

COVID-19 mRNA vaccine effectiveness against hospitalisation and death in veterans according to frailty status during the SARS-CoV-2 delta (B.1.617.2) variant surge in the USA: a retrospective cohort study. Tang F, Hammel IS, Andrew MK, Ruiz JG. Patients with frailty had lower levels of vaccination protection against COVID-19, compared with non-frail patients. Lancet Healthy Longev. 2022 Aug 1. Online ahead of print.

Impact of age, sex, race, and regionality on major clinical outcomes of COVID-19 hospitalized patients in the United States. Sundaram SS, Melquist S, Kalgotra P, Srinivasan S, Parasa S, Desai M, Sharma P. Advanced age, male sex, and high comorbidity predicted worse outcomes in hospitalized COVID-19 patients. BMC Infect Dis. 2022 July 29;22(1):659.

Telehealth complementary and integrative health therapies during COVID-19 at the U.S. Department of Veterans Affairs. Der-Mertirosian C, Shin M, Upham ML, Douglas JH Zeliadt SB, Taylor SL. Despite delivery issues or disadvantages of tele-complementary and integrative health self-care, Veterans’ use of these therapies grew substantially during the COVID-19 pandemic. Telemed J E Health. 2022 Jul 22. Online ahead of print.

Timing of a major operative intervention after a positive COVID-19 test affects postoperative mortality: Results from a nationwide, procedure matched analysis. Kougias P, Sharath SE, Zamani N, Brunicardi FC, Berger DH, Wilson MA. Patients undergoing major operations within eight weeks after a positive COVID-19 test have substantially higher post-operative 90-day mortality, compared to controls. Ann Surg. 2022 Jul 15. Online ahead of print.

⇑

Other Research

Quantitative chest CT assessment of small airways disease in post-acute SARS-CoV-2 infection. Cho JL, Villacreses R, Nagpal P, Guo J, Pezzulo AA, Thurman AL, Hamzeh NY et al. In survivors of COVID-19, small airways disease occurred independently of initial infection severity. Radiology. 2022 Jul;304(1):185-192.

Factors influencing uptake of telemental health via videoconferencing at high and low adoption sites within the Department of Veterans Affairs during COVID-19: A qualitative study. Connolly SL, Sullivan JL, Lindsay JA, Shimada SL, Heyworth L, Weaver KR, Miller CJ. A survey identified positive influences such as convenience and negative influence such as complexity that affected the uptake of videoconferencing for health care. Implement Sci Commun. 2022 Jun 20;3(1):66.

Self-reported health behaviors and risk perceptions following the COVID-19 vaccination rollout in the USA: An online survey study. Thorpe A, Fagerlin A, Drews FA, Shoemaker H, Scherer LD. COVID-19 vaccine rollout did not result in the rapid abandonment of protective behaviors or dramatic uptake of risk-increasing behaviors. Public Health. 2022 May 18;208:68-71.

Communications to promote interest and confidence in COVID-19 vaccines. Thorpe A, Fagerlin A, Drews FA, Butler J, Stevens V, Riddoch MS, Scherer LD. Messages with information on the benefits of vaccination, reframing the likelihood of side effects, and emphasizing that post-vaccine symptoms indicate the vaccine is working increased vaccine interest. Veterans were more interested and confident in vaccines than non-Veterans. Am J Health Promot. 2022 Apr 12. Online ahead of print.

An assessment of Veterans attitudes and willingness to receiving the COVID-19 vaccine: A mixed methods study. Gardner J, Brown G, Vargas-Correa J, Weaver F, Rubinstein I, Gordon HS. The study illustrates the complexity of patients’ deliberation about COVID-19 vaccination and may help physicians and other health care providers understand patients’ perspectives about vaccination. BMC Infect Dis. 2022 Mar 29;22(1):308.

⇑

Commentary

Estimated impact of the US COVID-19 vaccination campaign-Getting to 94% of deaths prevented. Jones M, Khader K, Branch-Elliman W. Substantial investments into national data infrastructure and research are needed to increase vaccine uptake and prevent more COVID-19 deaths. JAMA Netw Open. 2022 Jul 1;5(7):e2220391.

Approaches to long COVID care: the Veterans Health Administration experience in 2021. Gustavson AM, Eaton TL, Schapira RM, Iwashyna TH, Adly M, Purnell. Even well-resources health care systems such as VA are grappling with how to best address long COVID care. BMJ Mil Health. 2022 Jul 1;e002185.

Leveraging anthropological expertise to respond to the COVID-19 global mental health syndemic. Azevedo KJ, Riendeau RP, Sweet PA, Holmes SM. Anthropologists collaborating directly with mental health clinicians and the public can contribute to solutions to improve mental health issues exacerbated by the COVID-19 pandemic. Am Anthropol. 2022 Jun. Online ahead of press.

Awakening: The unveiling of historically unaddressed social inequities during the COVID-19 pandemic in the United States. Andrasik MP, Maunakea AK, Oseso L, Rodriguez-Diaz CE, Wallace S, Walters K, Yukawa M. Long-standing inequities paved the way for the disproportionate burdens of COVID-19 among people of color across the country. Infect Dis Clin North Am. 2022 Jun;36(2):295-308.

Smoking enhances suicide risk—A significant role in the COID-19 pandemic? Sher L. Tobacco smoking cessation may be needed to reduce suicidal behavior during and after the COVID-19 pandemic. QJM. 2022 Jan 5;114(11):767-769.

⇑

Active and Recently Completed Research

Clinical trials

As of November 2021, nearly 70 VA medical centers are involved in one or more COVID-19 clinical trials. Below are several examples. A full list of COVID-19 Clinical Trials in VA is also available.

• VA CURES—The wide-reaching VA CURES master protocol, launched in August 2020, enables a series of clinical trials across VA. The initial study examined the effects of convalescent plasma. VA CURES stands for “Coronavirus Research and Efficacy Studies.” The initiative aims to give Veterans faster access to potential COVID-19 treatments and to test their effectiveness. As a master protocol, VA CURES offers a standardized framework for studies on many potential treatments for COVID-19, without the need for a new study design and protocol each time. VA CURES now serves as a partnering network for trials and VA trial sites.

Related Articles


VA research spells out COVID's down-the-road risks for cardiovascular and mental health






Filtering out COVID-19






Amid shortage of face masks, researchers explore 3D options to guard against COVID-19, other infectious diseases






VA official encourages minorities to make educated decisions about participating in COVID-19 trials






Former Navy Surgeon General wants Veterans to know that vaccines are safe and effective for most






Veteran determined to help 'win this war' against COVID-19




• VA has been part of two major national research initiatives on COVID-19 vaccines and therapeutics:  Operation Warp Speed (OWS) and the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) initiative.
  • Through OWS and other efforts, VA was an active participant in several clinical trials designed to evaluate potential COVID-19 vaccines. These trials have included:
    • The Moderna/COVE trial, which took place at one VA site. In December 2020, Moderna obtained an emergency use authorization for its vaccine from the FDA.
    • The AstraZeneca trial, now closed to enrollment.
    • The Janssen ENSEMBLE trial, which included 17 VA sites and is now closed to enrollment. The vaccine received FDA emergency use authorization in late February 2021.
    • The Pfizer trial, now closed to enrollment. In December 2020, Pfizer obtained an emergency use authorization for its vaccine from the FDA.
    • The Novavax trial, now closed to enrollment in VA.
• ACTIV, led by the National Institutes of Health, brings together multiple groups within VA, the Department of Health and Human Services, and the Department of Defense, as well as outside organizations, to conduct large-scale clinical trials. VA is participating in two ACTIV protocols:
  • ACTIV-2 is a trial platform for outpatients with mild COVID-19 with risk of worsening illness. It is investigating multiple new drugs for potential COVID-19 treatment through clinical trials. ACTIV-2 has completed studies on six monoclonal antibodies, an antiviral, and an immunomodulator, and is currently studying multiple other possible therapeutics. Six VA sites have participated in ACTIV-2.
  • ACTIV-3 is a trial platform for inpatients with COVID-19. It is designed to test neutralizing monoclonal antibody and antiviral treatments in rapid succession. ACTIV-3 has completed trials of four monoclonal antibodies and one antiviral, and is enrolling participants for testing of a new antiviral. ACTIV-3 trials are also investigating patients with severe COVID-19 pneumonia, the drugs aviptadil and remdesivir alone or in combination as a COVID-19 treatment, and strategies for post-COVID-19 illness vaccination. Twenty VA sites have enrolled patients in ACTIV-3 studies.
• CDC SUPERNOVA—In partnership with the Centers of Disease Control and Prevention, VA has undertaken the Surveillance Platform for Enteric and Respiratory Infectious Organisms at the VA (SUPERNOVA) project. A network of five VA medical centers is conducting active and passive surveillance for acute gastroenteritis, a symptom of COVID-19 and other illnesses. Monitoring includes both laboratory-confirmed testing for SARS-CoV-2 and norovirus, as well as electronic health system data from patients’ charts. The project will help track pathogen distribution over time.
• Trials with industry—VA took part in a number of industry-sponsored studies of promising medications for COVID-19. These included, for example, studies of the drug tocilizumab with Hoffman-La Roche, and sarilumab with Regeneron. Both drugs are used in arthritis care and block an inflammatory protein known as IL-6.
• Remdesivir trial with NIH—VA sites took part in a randomized, placebo-controlled study of remdesivir and other medications for hospitalized patients with COVID-19, sponsored by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health.
• PURIFY blood filter technology—Scientists with VA, DOD, and partner institutions are testing a new technology called the Seraph 100 blood filter that may be able to filter out viral particles and harmful molecules from the bloodstreams of COVID-19 patients. The PURIFY program is a four-part, multi-site clinical evaluation that involves 13 participating sites across the U.S., including one VA medical center. Preliminary data suggests that severely ill patients treated with the Seraph filter had lower mortality rates than other patients.

⇑

Observational studies

• Natural history study—VA is collaborating with the Department of Defense on an observational, natural history study of COVID-19 illness titled “Epidemiology, Immunology and Clinical Characteristics of COVID-19” (EPIC³). Researchers are collecting data and biospecimens from volunteers for up to two years to better understand the clinical course of COVID-19. The study also aims to establish repositories of clinical data and specimens, along with a participant registry, to support future studies of COVID-19 and other health conditions. Recruitment at up to 16 sites began in July 2020.
• COVID-19 and cancer—The National Cancer Institute COVID-19 in Cancer Patients Study, or NCCAPS, is a natural history study of COVID-19 in people with cancer. In a natural history study, researchers follow people and collect medical and other information about them over time to learn more about how a disease and its symptoms develop and change. Diagnosis and treatment of a disease are not part of natural history studies. The knowledge gained through this study will help doctors better manage treatment for people with cancer and COVID-19 in the future. As part of the NCCAPS study, researchers will collect blood samples, medical information, and medical images from 2,000 people with cancer who also have COVID-19. Each person will be followed for up to two years to help doctors understand how cancer affects COVID-19 and COVID-19 affects cancer. The study is recruiting volunteers nationwide, including at 11 VA locations.

⇑

Data analysis projects

• COVID-19 Insights Partnership—VA is a key partner in the COVID-19 Insights Partnership, along with the departments of Energy (DOE) and Health and Human Services (HHS). The initiative aims to coordinate and share health data as well as research and expertise to aid in the fight against COVID-19.The Partnership creates a framework for VA and HHS to use DOE’s world-leading high-performance computing and artificial intelligence resources to conduct COVID-19 research and analyze health data.
• Million Veteran Program—VA’s Million Veteran Program (MVP) has deployed a COVID-19 questionnaire to participants to collect information about their experience with COVID-19. In addition, MVP has prioritized a series of research questions to examine the genetic basis of infection by SARS CoV-2; complications of infection; disease severity and outcomes; and response to various medications. MVP is working to identify disease mechanisms and new treatment targets for COVID-19. Given MVP's racially and ethnically diverse participant population (~ 20% African American and 7% Hispanic), the influence of race and ethnicity on disease susceptibility, severity, and outcomes is an integral part of the analyses.
• VA SHIELD—The VA Science and Health Initiative to Combat Infectious and Life-Threatening Diseases (VA SHIELD) is a comprehensive, secure biorepository of specimens and associated data related to COVID-19 and other emerging diseases. The specimens and data are available to authorized investigators to advance scientific understanding and support of developing diagnostic, therapeutic, and preventive strategies for use in clinical care.
• VA SeqCURE—VA SeqCURE, short for VA Sequencing Collaborations United for Research and Epidemiology, is a network of VA research labs funded by the American Rescue Plan of 2021. Five VA sites are included: Cleveland, Durham, Iowa City, Boise, and Temple. The network will generate genetic sequencing data for public health surveillance. Projects under VA SeqCURE will include studying the effectiveness of COVID-19 vaccines, analyzing antimicrobial-resistance organisms, and working with VA SHIELD to establish protocols for handling biospecimens.
• Synthesizing evidence from publications—Researchers from the HSR&D Evidence Synthesis Program are working to help synthesize publications about the novel coronavirus and COVID-19, and to translate that information quickly into usable guidance for clinicians. The ESP’s completed reports can be found here.
  Additional evidence reviews can be found at www.covid19reviews.org. The goal of this resource is to capture the work of evidence synthesis groups, like VA’s, around the US and the globe, and thereby avoid duplication of effort and maximize the contribution of these researchers. The catalog is maintained by the VA ESP Coordinating Center in Portland, Oregon. New evidence reviews and reviews in progress are identified through literature searching and correspondence with colleagues and content experts. The team has also set up a listserv to facilitate collaboration among systematic review researchers.
• International collaboration—Researchers with the VA Informatics and Computing Infrastructure team are participating in the Observational Health Data Sciences and Informatics (or OHDSI, pronounced "Odyssey") program, an international, interdisciplinary collaborative to maximize the value of health data through large-scale analytics.
• COVID-19 Observational Research Collaboratory (CORC)—A VA research initiative is bringing together VA experts to analyze the use and effects of COVID-19 drugs with clinical partners interested in the safety and efficiency of these therapies. VA’s Health Services Research and Development Service, Clinical Science Research and Development Service, and Cooperative Studies Programestablished the collaboratory soon after the pandemic took hold earlier this year. CORC is conducting a national three-year study of VA inpatients and outpatients diagnosed with COVID-19, compared with matched controls. The study will use electronic health record data and surveys to assess risk factors and long-term symptoms.
• Dementia patients—VA researchers in Providence have funding from the National Institute on Aging to study COVID-19 risk factors and outcomes among Veterans with dementia who live in VA community living centers.

⇑

Other research activities

• COVID-19 and mental health—In addition to studying how to prevent or treat COVID-19, VA is examining the mental health impact of the pandemic. To date, ORD has funded nearly 30 studies looking at mental, behavioral, and social health and COVID-19. Some are new projects focused wholly on COVID-19, whereas others are supplements to existing projects that are broader in scope. The following study titles indicate some of the themes being explored:
  • Inflammatory and Mental Health Sequelae of COVID-19 in Veterans
  • An Integrative Technology Approach to Home-Based Conjoint Therapy for PTSD  
  • Impact of COVID-19 On Mental Health, Relationship Functioning and VA Telemental Health Service Use in a Longitudinal Cohort Study    
  • Impact of COVID-19 and Social Distancing on Mental Health and Suicide Risk in Veterans
  • Piloting a Self-Help Intervention to Improve Veteran Mental Health During the COVID-19 Pandemic
  • Mixed-Methods Pilot Study of the Impacts of Telemental Healthcare for High-Risk Veterans with Opioid Use Disorder During COVID-19
  • Adapting Caring Contacts to Counteract Adverse Effects of Social Distancing among High-Risk Veterans During the COVID-19 Pandemic
  • Virtual Pain Care for High-Risk Veterans on Opioids During COVID-19 (and Beyond)
  • Changes in the Delivery of Evidenced-Based Psychotherapies for Depression and PTSD as the Result of the COVID-19 Pandemic
  • Impacts of COVID-19 on African American Veterans with Chronic Pain
• Biomedical studies—VA biomedical researchers are part of the fight against COVID-19. The following project titles illustrate the scope of the VA lab studies already completed or being conducted to better understand how the virus works, and to identify new ways to keep it from spreading and causing disease.
  • 3D-Printed Respirator Mask Performance with and without Virus Inactivation 
  • A Safe Validation to Test the Efficacy of Disinfectants on Reusable 3D-Printed Face Masks During the COVID-19 Pandemic 
  • Leukocyte Rewiring as a Mechanism of COVID-19-ARDS 
  • Viral and Immune Dynamics of Sars-Cov-2 Infection in Moderate and Severe COVID-
  • Predictive Immune and Airway Monitoring in Healthcare Workers and Hospitalized COVID-19 Patients 
• Boosting the VA supply chain—Rehabilitation researchers are helping to build a more resilient supply chain for VA. Researchers from several centers are involved, such as the Human Engineering Research Laboratories (HERL) in Pittsburgh; the Center for Limb Loss and Mobility at the Puget Sound VA; the Minneapolis Adaptive Design and Engineering Program; and the Advanced Platform Technology Center in Cleveland. Partners in this effort include the VA Innovation Ecosystem, the U.S. Food and Drug Administration, the National Institutes of Health, and America Makes. These researchers and their colleagues have been designing, fabricating, and evaluating personal protective equipment (PPE) and other supplies to support VA’s response to this pandemic, such as masks, face shields, desk shields, nasal testing swabs. In many cases, 3D printing is involved.

⇑

COVID-19 work highlighted on HSR&D site

For a concise overview of current VA Health Services Research and Development (HSR&D) efforts on COVID-19, visit COVID-19 Efforts.

⇑

Useful links

• VA COVID-19 Research Volunteer List
• Department of Veterans Affairs Public Health
• Centers for Disease Control and Prevention
• COVID-19 Reviews [maintained by VA ESP]

⇑

Questions about the R&D website? Email the Web Team.

Any health information on this website is strictly for informational purposes and is not intended as medical advice. It should not be used to diagnose or treat any condition.